We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

53 hedge funds and large institutions have $250M invested in Corvus Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

83.62% more ownership

Funds ownership: 0% → 83.62% (+84%)

18% more funds holding

Funds holding: 45 → 53 (+8)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 16

7% less capital invested

Capital invested by funds: $267M → $250M (-$17.4M)

Holders
53
Holders Change
+8
Holders Change %
+17.78%
% of All Funds
1.32%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
15
Reduced
16
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$19.4M
2
EAM
EverPoint Asset Management
Connecticut
+$6.35M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$549K
4
EIM
Essex Investment Management
Massachusetts
+$324K
5
BFA
BlackRock Fund Advisors
California
+$244K

Top Sellers

Rank Fund Capital Flow
1
BA
BlackRock Advisors
Delaware
-$6.51M
2
ACA
Avoro Capital Advisors
New York
-$787K
3
Millennium Management
Millennium Management
New York
-$778K
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$391K
5
CAM
Cormorant Asset Management
Massachusetts
-$237K
Name Holding Trade Value Shares
Change 		Change in
Stake
LTFS
26
Ladenburg Thalmann Financial Services
Florida
$220K +$89.7K +5,900 +62%
BIM
27
BlackRock Investment Management
Delaware
$177K – – –
Goldman Sachs
28
Goldman Sachs
New York
$173K -$191K -12,580 -51%
Morgan Stanley
29
Morgan Stanley
New York
$142K +$138K +9,063 +998%
PCM
30
Prelude Capital Management
New York
$134K +$143K +9,402 New
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$97K -$3.04K -200 -3%
BG
32
BlackRock Group
United Kingdom
$72K – – –
TCIM
33
TIAA CREF Investment Management
New York
$72K +$6.51K +428 +9%
Citigroup
34
Citigroup
New York
$62K +$46.8K +3,077 +242%
TA
35
Teachers Advisors
New York
$51K – – –
Bank of America
36
Bank of America
North Carolina
$41K +$8.06K +530 +23%
AIG
37
American International Group
New York
$27K -$76 -5 -0.3%
Deutsche Bank
38
Deutsche Bank
Germany
$27K +$22K +1,444 +264%
TRCT
39
Tower Research Capital (TRC)
New York
$21K +$21.7K +1,427 New
UBS Group
40
UBS Group
Switzerland
$19K +$20.7K +1,360 New
SO
41
STRS Ohio
Ohio
$15K – – –
Wells Fargo
42
Wells Fargo
California
$13K -$7.6K -500 -36%
BJ
43
BlackRock Japan
Japan
$12K – – –
CHP
44
Cable Hill Partners
Oregon
$11K – – –
Legal & General Group
45
Legal & General Group
United Kingdom
$11K +$11.5K +754 New
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$10K – – –
CSS
47
Cubist Systematic Strategies
Connecticut
$8K +$8.03K +528 New
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$6K – – –
CMBA
49
C.M. Bidwell & Associates
Hawaii
$3K -$127K -8,356 -97%
BlackRock
50
BlackRock
New York
$3K -$3.04K -200 -46%
1
2
3

CRVS Hedge Fund Activity: Q4 2016 in Review

53 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2016, worth a combined $250M — down 6.5% from $267M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CRVS positions and 0 closed out — a net gain of 9 holders — while 15 added to existing stakes and 16 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $19.4M. The largest seller was BlackRock Advisors, cutting an estimated $6.51M.

  • 53 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2016, up from 45 in Q3 2016.
  • Funds reported $250M of Corvus Pharmaceuticals stock for Q4 2016, down 6.5% quarter-over-quarter.
  • 9 funds opened new Corvus Pharmaceuticals positions in Q4 2016 and 0 closed out, a net change of +9 holders.
  • The largest Corvus Pharmaceuticals buyer in Q4 2016 was Fidelity Investments, an estimated $19.4M added.
  • The largest Corvus Pharmaceuticals seller in Q4 2016 was BlackRock Advisors, an estimated $6.51M sold.

Based on aggregated 13F filings for Q4 2016.